The Company’s operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, ...

HCW11-040 is a first-in-class pembrolizumab-based, tetra-valent immune checkpoint inhibitor designated as Company’s franchise ...

Apartment Investment and Management Company ("Aimco") announced today the conclusion of the strategic review process and third quarter results for ...